Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
- 20 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Hematologic Malignancy Reports
- Vol. 5 (2), 62-69
- https://doi.org/10.1007/s11899-010-0047-9
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is characterized by the presence of a serum monoclonal (M) protein level less than 3 g/dL, less than 10% clonal plasma cells in the bone marrow, and the absence of hypercalcemia, renal insufficiency, anemia, or bone lesions attributable to a clonal plasma cell disorder. Patients may be tested for a monoclonal gammopathy by serum protein electrophoresis, immunofixation, and the free light chain (FLC) assay. The prevalence of MGUS is 3% for persons more than 50 years of age and 5% in those more than 70 years of age. The risk of progression to multiple myeloma or a related disorder is 1% per year. The size and type of M protein, the number of bone marrow plasma cells, and the results of the FLC ratio are independent risk factors for progression. Smoldering multiple myeloma (SMM) is a more advanced premalignant phase than MGUS and is characterized by more than 3 g/dL of serum M protein, more than 10% clonal plasma cells in the bone marrow, or both, with no evidence of end-organ damage.Keywords
This publication has 42 references indexed in Scilit:
- Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple MyelomaJournal of Clinical Oncology, 2009
- Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceBlood, 2009
- Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health StudyBlood, 2009
- A monoclonal gammopathy precedes multiple myeloma in most patientsBlood, 2009
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Prevalence of Monoclonal Gammopathy of Undetermined Significance: Study of 52,802 Persons in Nagasaki City, JapanMayo Clinic Proceedings, 2007
- Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in GhanaMayo Clinic Proceedings, 2007
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaThe New England Journal of Medicine, 2007
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceThe New England Journal of Medicine, 2002